Cardiol Therapeutics (TSE:CRDL) Shares Down 8.7%

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) traded down 8.7% on Thursday . The stock traded as low as C$2.42 and last traded at C$2.51. 139,820 shares were traded during trading, a decline of 8% from the average session volume of 152,202 shares. The stock had previously closed at C$2.75.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating on shares of Cardiol Therapeutics in a report on Monday, April 22nd.

Cardiol Therapeutics Price Performance

The company has a market capitalization of C$173.19 million, a PE ratio of -5.34 and a beta of 0.68. The firm has a fifty day moving average of C$2.98 and a two-hundred day moving average of C$2.18. The company has a current ratio of 2.81, a quick ratio of 6.84 and a debt-to-equity ratio of 0.83.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.